<DOC>
	<DOCNO>NCT03024450</DOCNO>
	<brief_summary>Trastuzumab plus chemotherapy effective therapy HER2 positive advance gastric cancer ( AGC ) . However , efficacy routine trastuzumab therapy association clinicopathologic factor remain unclear . The object study determine whether addition trastuzumab first-line chemotherapy improve efficacy compare chemotherapy alone HER2 positive AGC .</brief_summary>
	<brief_title>Trastuzumab Based Therapy HER2 Positive AGC</brief_title>
	<detailed_description>A total 98 patient HER2 positive AGC enrol prospective observational study . All patient treat trastuzumab plus chemotherapy first line therapy . Efficacy safety trastuzumab analyze , clinical pathological data collect evaluate potential prognostic factor progressive free survival .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1. pathology medical imageology proven advance gastric adenocarcinoma , inoperable ; 2. receive trastuzumab plus chemotherapy firstline palliative chemotherapy ; 3. measurable lesion diameter 20 mm use conventional compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan 10 mm use spiral CT scan ; 4 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 02 ; 5. leave ventricular ejection fraction ( LVEF ) 50 percent ; 6. sufficient bone marrow , liver renal function . 1. receive previous systemic therapy advance disease ( except adjuvant/neoadjuvant chemotherapy complete least 6 month enrollment ) ; 2. trastuzumab base adjuvant/neoadjuvant therapy ; 3. treatment anticancer therapy ( lapatinib , immunotherapy , etc ) ; 4. patient heart failure , coronary artery disease myocardial infarction within previous 6 month . 5. trastuzumab base first line therapy start beyond 4 week first diagnosis AGC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>prognosis</keyword>
</DOC>